...
首页> 外文期刊>British Journal of Cancer >The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study
【24h】

The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study

机译:三周他莫昔芬治疗对原发性乳腺肿瘤中雌激素受体水平的影响:流式细胞术研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The effect of 3-week, preoperative tamoxifen treatment on oestrogen receptor (ER) levels, expressed by primary breast tumours, was examined. Patients (age-matched) with breast cancer, confirmed by fine-needle aspiration, were either treated with 20 mg ml(-1) oral tamoxifen per day or received no medication in the 3-week interval between assessment and surgery. Quantification of ER using flow cytometry was performed on the surgically removed tumour samples from tamoxifen-treated (n = 40) and control (n = 38, untreated) patient groups. The tumours were mechanically disaggregated, and saponin treatment rendered these cells permeable to antibodies. Using dual-parameter labelling with a FITC-conjugated antibody (NCL-5D3) directed against cytokeratin 8/18/19 and a biotinylated antibody (DAKO-ER 1D5) directed against the oestrogen receptor, ER quantification was determined on a number of receptors per cell basis. Using QC quantum bead standards, ER levels in the epithelial cell population, the non-epithelial cell population and the whole-cell population (ER+) were calculated. ER levels were significantly lower in the total cell population than tamoxifen-treated patients (P = 0.002) when compared with the control (untreated) group. By using a gating procedure using 5D3 antibody positivity, a significantly lower level was detected on examining the cytokeratin-positive population alone (P = 0.006). Using a complementary gating technique, ER levels were quantified in the cytokeratin-negative cell population. Examination of this group of cells showed no significant difference between the levels of oestrogen receptor found in the tamoxifen-treated and untreated groups (P = 0.4). We have demonstrated that ER levels can be monitored by flow cytometry. ER levels in patients treated with tamoxifen 3 weeks before operation are significantly lower than in a comparative group of patients who received no drug. Furthermore, the most significant difference in receptor levels is seen by quantification of total ER levels expressed by all the tissue.
机译:检查了术前三周他莫昔芬治疗对原发性乳腺肿瘤表达的雌激素受体(ER)水平的影响。细针穿刺证实的乳腺癌患者(年龄匹配)每天接受20 mg ml(-1)口服他莫昔芬治疗,或者在评估和手术之间的3周间隔内不接受任何药物治疗。使用流式细胞术对从他莫昔芬治疗(n = 40)和对照组(n = 38,未治疗)患者组中手术切除的肿瘤样品进行了ER定量。机械地分解肿瘤,并且皂苷处理使这些细胞可渗透抗体。使用针对细胞角蛋白8/18/19的FITC偶联抗体(NCL-5D3)和针对雌激素受体的生物素化抗体(DAKO-ER 1D5)进行双参数标记,确定了ER定量细胞基础。使用QC量子珠标准物,计算上皮细胞群,非上皮细胞群和全细胞群(ER +)中的ER水平。与对照组(未治疗)组相比,总细胞群体中的ER水平显着低于他莫昔芬治疗的患者(P = 0.002)。通过使用采用5D3抗体阳性的门控程序,仅检查细胞角蛋白阳性人群时,检测到的水平明显较低(P = 0.006)。使用互补门控技术,可在细胞角蛋白阴性细胞群中量化ER水平。对这组细胞的检查显示,在他莫昔芬治疗组和未治疗组中,雌激素受体水平之间无显着差异(P = 0.4)。我们已经证明可以通过流式细胞仪监测ER水平。术前3周接受他莫昔芬治疗的患者的ER水平明显低于未接受药物治疗的对照组。此外,通过定量所有组织表达的总ER水平,可以看到受体水平的最显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号